Among the 12 top-scoring genes whose knockdown significantly affected colon cancer proliferation, BRD4 was deemed particularly attractive to pursue, given that BRD4 small-molecule inhibitors have entered clinical trials for several hematological malignancies and few reports have studied BRD4 in CRC [157,158]. This evidence concerns the gene BRD4 and colorectal carcinoma.